A patient with hepatocellular carcinoma(HCC) staged Barcelona Clinic for Liver Cancer stage B started chemotherapy because of intrahepatic recurrence after hepatic segmentectomy. Regorafenib was started as a second-line treatment due to refractory to sorafenib treatment, but was discontinued after 26 months due to side effects. After two years of follow-up, the patients achieved unexpected long-term regression. We present the potential of regorafenib effect for anti-tumor immunity through possible pharmacological mechanisms.


中文翻译：

---

索拉非尼难治性肝细胞癌停用瑞戈非尼后长期消退

一位在巴塞罗那临床分期为肝癌 B 期的肝细胞癌 (HCC) 患者因肝段切除术后肝内复发开始化疗。由于索拉非尼治疗难治，瑞戈非尼开始作为二线治疗，但由于副作用在 26 个月后停药。经过两年的随访，患者取得了意想不到的长期消退。我们通过可能的药理学机制展示了瑞戈非尼抗肿瘤免疫作用的潜力。